W. Krause

[Long-term testing of 2-(2,6-dichlorphenylamino)-2-imidazoline hydrochloride with special reference to the effect on blood pressure and carbohydrate metabolism].

H. Renner, D. Krämer, W. Krause, 1970, Arzneimittel-Forschung.

Fungaemia and funguria after oral administration of Candida albicans.

W. Krause, H. Matheis, K. Wulf, 1969, Lancet.

CNS drug specificity as determined by the mouse intravenous pentylenetetrazol technique.

J. W. Bastian, N. Ercoli, W. Krause, 1959, The Journal of pharmacology and experimental therapeutics.

[Experimental fungiemia and fungiuria by oral administration of large amounts of Candida albicans in healthy man (self-experiment)].

W. Krause, H. Matheis, K. Wulf, 1969, Arzneimittel-Forschung.

In-vitro and in-vivo characterisation of two sustained release formulations for the antidepressant rolipram.

M. Pfeffer, N. Sauerbrey, W. Krause, 1990, Arzneimittel-Forschung.

[Comparative in vitro and in vivo studies on the permeation and penetration of ketoprofen and ibuprofen in human skin].

E. Haltner, U. Bock, W. Krause, 2004, Arzneimittel-Forschung.

Pharmacokinetics of the anxiolytic beta-carboline derivative abecarnil in the mouse, rat, rabbit, dog, cynomolgus monkey and baboon. Studies on species differences.

H. Mengel, W. Krause, 1990, Arzneimittel-Forschung.

Pharmacokinetics and acute toleration of the beta-carboline derivative abecarnil in man.

T. Duka, B. Schütt, W. Krause, 1990, Arzneimittel-Forschung.